U.S. News Room

Press Releases

Daiichi Sankyo, Inc. To Establish New U.S. Headquarters in Basking Ridge, New Jersey

Download the PDF version of Article

April 18, 2016

Parsippany and Edison, N.J. – April 18, 2016 – Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., today announced that it will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, NJ. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.

"Uniting our New Jersey-based personnel into a single location not only makes us more efficient, but it will also further strengthen collaboration among teams working across the entire life cycle of our medicines," said Glenn Gormley, MD, PhD, Chairman of the Board and President, Daiichi Sankyo, Inc.  "We have enjoyed being a part of the Parsippany and Edison communities and we look forward to what the future holds in our new headquarters," he added.

Daiichi Sankyo, Inc. is comprised of U.S.-based development functions, currently located in Edison, New Jersey, as well as all U.S. commercial departments, currently located in Parsippany, New Jersey.  The new office will be located at 211 Mt. Airy Road, Basking Ridge, New Jersey.  The company expects to begin moving employees to the new location in 2017.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit:  Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit




Refer to

Kimberly Wix
(973) 944-2338

Back to press releases